为探究植物乳杆菌发酵豆乳缓解大鼠多囊卵巢综合征症状(polycystic ovary syndrome,PCOS)的能力,采用来曲唑灌胃的方式构建PCOS大鼠模型,并以此模型评价了3株植物乳杆菌发酵豆乳对PCOS大鼠体重、卵巢病理学、性激素水平、糖脂代谢等的影响。结果表明,来曲唑给药后大鼠体重以及卵巢重量均显著增加,卵巢呈多囊样改变,性激素水平以及生化指标异常。3株植物乳杆菌发酵豆乳干预后均不同程度减轻了来曲唑引起的大鼠卵巢病变,降低PCOS大鼠血清睾酮、总胆固醇、甘油三酯及低密度脂蛋白胆固醇水平。其中,植物乳杆菌CCFM1019发酵豆乳可以显著增加血清中雌二醇水平,降低谷草转氨酶(aspartate aminotransferase,AST)含量,而植物乳杆菌LP4发酵豆乳可以显著降低血清中促黄体生成素含量以及谷丙转氨酶、AST含量。这些不同植物乳杆菌发酵的豆乳能在不同程度上缓解大鼠PCOS症状。
石刘婷
,
贺禹丰
,
杨羽倩
,
祁亚劲
,
鲁佳欣
,
詹语
,
郭敏
,
王慧玲
,
赵建新
,
张灏
,
王刚
,
陈卫
. 植物乳杆菌发酵豆乳对多囊卵巢综合征大鼠的影响[J]. 食品与发酵工业, 2022
, 48(4)
: 165
-170
.
DOI: 10.13995/j.cnki.11-1802/ts.027940
In order to explore the capability of Lactobacillus plantarum fermented soymilk in alleviating the symptoms of polycystic ovary syndrome (PCOS) in mice, letrozole was used to construct PCOS rat model. The effects of soymilk fermented by three strains of L. plantarum on body weight, ovarian pathology, sex hormone levels, glucose and lipid metabolism of PCOS rats were evaluated separately. The results indicated that the body weight and ovarian weight of rats increased significantly after letrozole administration. The ovaries showed polycystic changes. And the levels of sex hormones and biochemical indicators were abnormal. The intervention of L. plantarum fermented soymilk alleviated the ovarian lesions in rats caused by letrozole and reduced the serum testosterone, triglyceride, total cholesterol and low density lipoprotein levels in PCOS rats. In addition, the L. plantarum CCFM1019 fermented soymilk could significantly increase the serum estradiol level and reduce the content of aspartate aminotransferase (AST), while soymilk fermented by L. plantarum LP4 significantly reduced the content of luteotropic hormone, alanine aminotransferase and AST in serum. The soymilk fermented by different L. plantarum strains can relieve the symptoms of PCOS in rats to varying degrees.
[1] GUO Y J, QI Y E, YANG X F, et al.Association between polycystic ovary syndrome and gut microbiota[J].PLoS One, 2016, 11(4):e0153196.
[2] 刘爱敏. 达英-35联合来曲唑治疗难治性多囊卵巢综合征患者的临床疗效分析[J].现代诊断与治疗, 2020, 31(22):3 589-3 591.
LIU A M.Analysis of clinical efficacy of daiin-35 combined with letrozole in the treatment of refractory polycystic ovary syndrome[J].Modern Diagnosis and Treatment, 2020, 31(22):3 589-3 591.
[3] MEIER R K.Polycystic ovary syndrome[J].The Nursing Clinics of North America, 2018, 53(3):407-420.
[4] 李天鹤, 武香梅, 刘瑞霞, 等.多囊卵巢综合征造模药物对大鼠内分泌和组织结构影响的初步比较[J].生殖医学杂志, 2020, 29(12):1 633-1 639.
LI T H, WU X M, LIU R X, et al.Comparison of effects of three drugs for modeling polycystic ovary syndrome on endocrine and tissue structure in rats[J].Journal of Reproductive Medicine, 2020, 29(12):1 633-1 639.
[5] SALEEM F, RIZVI S W.New therapeutic approaches in obesity and metabolic syndrome associated with polycystic ovary syndrome[J].Cureus, 2017, 9(11):1 844-1 852.
[6] LEGRO R S, ARSLANIAN S A, EHRMANN D A, et al.Diagnosis and treatment of polycystic ovary syndrome:An endocrine society clinical practice guideline[J].Journal of Clinical Endocrinology & Metabolism, 2013, 98(12):4 565-4 592.
[7] LEVIN D, BELL S, PUKKALA E, et al.Pioglitazone and bladder cancer risk:A multipopulation pooled, cumulative exposure analysis[J].Diabetologia, 2015, 58(3):493-504.
[8] LIU R, ZHANG C H, SHI Y, et al.Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome[J].Frontiers in Microbiology, 2017, 8:e1002687.
[9] INSENSER M, MURRI M,DEL CAMPO R, et al.Gut microbiota and the polycystic ovary syndrome:Influence of sex, sex hormones, and obesity[J].The Journal of Clinical Endocrinology & Metabolism, 2018, 103(7):2 552-2 562.
[10] YURTDAŞ G,AKDEVELIOĞLU Y.A new approach to polycystic ovary syndrome:The gut microbiota[J].Journal of the American College of Nutrition, 2019, 39(2):371-382.
[11] QI X Y, YUN C Y, SUN L L, et al.Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome[J].Nature Medicine, 2019, 25(8):1 225-1 233.
[12] KARAMALI M, EGHBALPOUR S, RAJABI S, et al.Effects of probiotic supplementation on hormonal profiles, biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome:A randomized, double-blind, placebo-controlled trial[J].Archives of Iranian Medicine, 2018, 21(1):1-7.
[13] SHAMASBI S G, GHANBARI-HOMAYI S, MIRGHAFOURVAND M.The effect of probiotics, prebiotics, and synbiotics on hormonal and inflammatory indices in women with polycystic ovary syndrome:A systematic review and meta-analysis[J].European Journal of Nutrition, 2020, 59(2):433-450.
[14] HE Y F, WANG Q Q, LI X, et al.Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone related gut microbiota[J].Food & Function, 2020,11(6):5 192-5 204.
[15] KAFALI H, IRIADAM M, OZARDALI I, et al.Letrozole-induced polycystic ovaries in the rat:A new model for cystic ovarian disease[J].Archives of Medical Research, 2004, 35(2):103-108.
[16] ZHANG J C, SUN Z H, JIANG S M, et al.Probiotic Bifidobacterium lactis V9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain axis[J].mSystems, 2019.DOI:10.1128/mSystems.00017-19.
[17] LI X, FENG Y, LIN J F, et al.Endometrial progesterone resistance and PCOS[J].Journal of Biomedical Science, 2014, 21:2.
[18] 徐智睿. PCOS患者血脂、激素、糖耐量和胰岛素抵抗指数及其与BMI、GAUC的相关性分析[J].标记免疫分析与临床, 2018, 25(6):804-807.
XU Z R.The analysis of serum lipids, hormones, glucose tolerance and insulin resistance index in patients with PCOS and their correlations with BMI and GAUC[J].Labeled Immunoassays and Clinical Medicine, 2018, 25(6):804-807.
[19] 谷郁婷. PCOS合并胰岛素抵抗的血脂与生理生化指标相关性分析[J].齐齐哈尔医学院学报, 2014, 35(22):3 310-3 311.
GU Y T.The relationship between blood lipid and insulin resistance in patients with PCOS[J].Journal of Qiqihar Medical College, 2014, 35(22):3 310-3 311.
[20] RASHAD N M, EL-SHAL A S, AMIN A I, et al.Effects of probiotics supplementation on macrophage migration inhibitory factor and clinical laboratory feature of polycystic ovary syndrome[J].Journal of Functional Foods, 2017, 36:317-324.
[21] 颜秀敏, 刘凯亮, 高心雨, 等.不同剂量大豆异黄酮对多囊卵巢综合征大鼠的干预效果研究[J].实用妇产科杂志, 2020, 36(8):626-630.
YAN X M, LIU K L, GAO X Y, et al.Therapeutic effect of different doses of soy isoflavoneson PCOS rats[J].Journal of Practical Obstetrics and Gynecology, 2020, 36(8):626-630.
